Short answer
Tonix Pharmaceuticals Holding Corp. (TNXP) filed an 8-K current report with the SEC on July 13, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Standard Regulation FD disclaimer language, not substantive investor disclosure.
Tonix Pharmaceuticals Holding Corp. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Standard Regulation FD disclaimer language, not substantive investor disclosure
- No operational, financial, clinical, or corporate event information provided
Item 8.01 · Other Events
- PBM agreement effective January 1, 2027, adding TONMYA coverage for approximately 9 million Medicare Part D beneficiaries
- Medicaid coverage currently reaches approximately 73 million beneficiaries across most states
- Expected government and commercial coverage of approximately 145 million individuals by January 1, 2027
- Broader reimbursement access could expand TONMYA’s addressable market and commercialization potential
- Coverage timing and reach remain forward-looking, with execution and adoption risks disclosed by the company
Item EX-99.1 · Exhibit EX-99.1
- Managed Medicare agreement effective January 1, 2027, adding approximately 9 million covered lives
- TONMYA coverage expected to reach approximately 145 million lives, or 46% of 314 million covered lives
- Sales force expansion of 50 representatives planned by mid-third quarter 2026, increasing total field force to approximately 150
- Broader reimbursement access could support prescription growth, but commercial impact depends on payer utilization and launch execution
- TONMYA carries important safety restrictions, including contraindications with MAO inhibitors and serotonin-syndrome risk with serotonergic drugs
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tonix Pharmaceuticals Holding Corp. 8-K filings
Get the next TNXP 8-K as it lands
Follow TNXP for push alerts, or ask the research agent what this filing means.